AI Science Tracker

Generative deep learning discovers the RIPK1 inhibitor RI-962 with an unreported scaffold

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University; West China School of Pharmacy, Sichuan University · 12 Nov 2022 · medicine

Discovery

Generative deep learning discovers the RIPK1 inhibitor RI-962 with an unreported scaffold

A target-conditioned generative deep-learning model based on a distribution-learning conditional recurrent neural network generated a tailored compound library that was screened for RIPK1 inhibition. The study reports RI-962 as a potent inhibitor with a previously unreported scaffold, validated in vitro for protection from necroptosis and in vivo in two inflammatory models.

Technology: Generative deep-learning distribution-learning conditional recurrent neural network (GDL cRNN)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The study reports RI-962 as a potent inhibitor with a previously unreported scaffold, validated in vitro for protection from necroptosis and in vivo in two inflammatory models.
  • Still unknown: Evidence is preclinical: cellular necroptosis assays and two inflammatory mouse models do not establish human efficacy or safety. The paper identifies one leading molecule from a generated library; it does not validate generative-model performance across targets generally.
  • AI role: The GDL cRNN generated a target-tailored virtual compound library; virtual screening and subsequent chemical synthesis and bioactivity assays selected RI-962. This provides direct experimental testing of a model-generated molecule rather than a prediction-only hit.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/36371441/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 114 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.